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946ABSTRACT
Introduction. With the introduction of combination antiretroviral therapy (cART),
prognosis of human immunodeﬁciency virus (HIV) infection has been improved and kid-
ney transplantation (KT) in HIV-positive patients became possible.
Methods. We reviewed the demographic, clinical, laboratory, and therapeutic data of all
the HIV-infected patients who underwent KT between 2009 (ﬁrst KT in Portugal in a HIV-
infected patient) and May 2014. Case accrual was through all Portuguese KT centers where
a KT in an HIV-infected patient was performed. Patients were transplanted following the
American and Spanish guideline recommendations that included maintenance on cART,
undetectable plasma HIV RNA copies, and absolute CD4 counts of 200 cells/mL in
the last 6 months.
Results. Fourteen KT were performed on men and 3 on women. The mean age of pa-
tients at the time of transplantation was 49.9  11.7 years. HIV status was known for 12  5
years. Eight patients had AIDS in the past and all patients received grafts from deceased
donors. Twelve patients (64.7%) underwent induction therapy with basiliximab and 2 pa-
tients experienced early graft loss. In 2 patients, humoral rejection was diagnosed and in 3
patients, cellular rejection. Two patients died and an additional patient had early graft loss.
Conclusion. KT is a possible, but challenging, renal replacement therapy in selected HIV-
positive patients. Even in those with AIDS criteria in the past, when the disease is controlled,
and after the reconstitution of the immune system with cART, KT can be performed.
Nevertheless, the riskebeneﬁt ratio for each patient needs to be taken in consideration.*Address correspondence to Sara Querido, Nephrology, Cen-
tro Hospitalar do Médio Tejo, Av. Xanana Gusmão - Apartado 45,
2350 - 754 - Torres Novas, Portugal. E-mail: saraqueridoconde@
gmail.comWITH THE INTRODUCTION of combination antire-troviral therapy (cART) in 1996, prognosis of human
immunodeﬁciency virus (HIV) infection has improved owing
to a sustained suppression of HIV replication and immuno-
logic recovery and the risk of opportunistic infections became
very low [1,2]. Therefore, kidney transplantation (KT) became
possible in HIV-positive patients. In the United States and
Europe, approximately 1%e1.5% of patients with end-stage
renal disease (ESRD) are infected with HIV [3,4]. In
January 2014, 151 HIV-positive patients were undergoing
dialysis inPortugal and 9 of these patientswere onawaiting list
for KT [5].
Several scientiﬁc societies have developed guidelines
regarding organ transplantation in these patients. The5
.org/10.1016/j.transproceed.2015.03.029candidate for KT should not suffer from any condition
included in category C that deﬁne AIDS, CD4 lymphocyte
count should be >200 cells/mL, and HIV viral load should be
undetectable [6,7] for a period of 6 months. Social and
psychiatric evaluations must be done and, usually, in drug
abusers, a period of abstinence of >2 years is recommended.
Furthermore, although the frequency of AIDS deﬁning
events has decreased, noneAIDS-related events, including
ESRD, has increased. HIV-infected patients may sufferª 2015 by Elsevier Inc. All rights reserved.
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CrCL MDRD (mL/min/1.73 m2)
6/12/24/36 mo Graft Loss/Patient Death
1 M 57 1998 AHR BK 34 36/33/31/d No
2 M 51 2002 No No 21 83/95/d/d No
3 M 66 1999 No No 14 53/49/d/d No
4 M 43 1987 No No 16 54/60/d/d No
5 M 66 1998 No No 3 d No
6 F 35 1996 No No 3 d No
7 M 38 1994 No HCV 0 d Death/graft loss: hypovolemic shock
8 M 65 2003 No No 0 d Graft loss: vascular thrombosis
9 M 32 2009 No No 15 35/63/d/d No
10 M 65 2003 AHR No 8 53/d/d/d No
11 F 48 2005 ACR No 6 76/d/d/d No
12 M 56 1999 ACR No 3 d No
13 M 44 2005 ACR No 52 75/43/58/49 No
14 M 45 2000 No No 42 91/66/72/88 No
15 F 58 2003 No No 24 63/61/52 No
16 M 47 2002 No No 21 91/94/d/d No
17 M 64 2006 No No 2 d Death: H1N1 infection
Abbreviations: ACR, acute cellular rejection; AHR, acute humoral rejection; CrCL, creatinine clearance; F, female; HCV, hepatitis C virus; HIV, human immunode-
ﬁciency virus; M, male; mo, months; MDRD, Modiﬁcation of Diet in Renal Disease.
TRANSPLANTATION IN HIV-INFECTED PATIENTS 947from kidney failure owing to usual causes of ESRD or
directly owing to HIV infection, including HIV-related
nephropathy (HIVAN), immune complexemediated
glomerulonephritis, and thrombotic microangiopathy [8].
Additionally, HIV-infected patients may suffer kidney
injury through complications of infection or nephrotoxicity
of antiretroviral therapy [9].
In our study, we evaluated the characteristics and evolution
of all patients who received a renal allograft in Portugal
between 2009 and May 2014.METHODS
We reviewed the charts of all HIV-infected patients who had un-
dergone KT between 2009 (ﬁrst KT in Portugal in a HIV-infected
patient) and May 2014. We analyzed HIV subtype, evolution of
the viral disease, etiology of the renal disease, diabetes, time on
dialysis, immunologic compatibility, coinfection with cytomegalo-
virus and BK, immunosuppression and antiretroviral therapies
before and after KT, rejection episodes, graft function, and graft
and patient survival. Renal function was expressed as estimated
glomerular ﬁltration rate (eGFR) using the Chronic Kidney Disease
Epidemiology Collaboration equation.
Statistics
Statistical parameters were calculated using Microsoft Ofﬁce Excel
2011 and were used the following parameters: percentage, average,
or standard deviation.RESULTS
We identiﬁed 17 KT in 16 different patients (1 re-KT). Six
KT were performed in Hospital de Santa Cruz, 6 KT (in 5
patients) in Hospital Curry Cabral, 4 KT in Hospital de São
João, and 1 KT in Hospital Garcia de Orta, which was the
ﬁrst performed in Portugal, in November 2009.Of 17 KT, 14 were performed in men. The mean age of
patients at the time of transplantation was 49.9  11.7 years;
10 patients were Caucasian and 14 KT were performed on
HIV type 1 patients; 2 patients were HIV type 2 positive [10].
HIV status was known for 12 5 years; the HCV co infection
rate was 11.8% (2/17). Four patients had HIVAN, 2 patients
had autosomal-dominant polycystic kidney disease. The
other 3 had immunoglobulin (Ig)A nephropathy, diabetic
nephropathy, and chronic glomerulonephritis. The etiology
was uncertain in 8 patients whom had only known their
kidney disease already in stage 5, precluding a histologic
diagnosis. The median time on dialysis was 115.8  65.7
months; 8 patients had previously fulﬁlled diagnostic criteria
for AIDS in the past. However, AIDS criteria were not
present for the 6 months before KT. Only 1 patient was not
taking cART therapy before KT, but he started antiretroviral
treatment after receiving the allograft. Five patients were
under antiretroviral protocols that included ritonavir-
boosted protease inhibitors. Undetectable viral load and a
CD4 lymphocyte count of 200 cells/mL were obtained in all
recipients. All patients received grafts from deceased donors.
All recipients and all donors had anti-cytomegalovirus IgG
antibodies; 14 patients had >3 HLA mismatches with the
donor and in 2 patients anti-HLA class I and II antibodies
were identiﬁed. Six patients had a panel reactive antibody of
>25%. Twelve patients (64.7%) received induction therapy
with basiliximab, 3 patients with polyclonal antibodies and 1
patients received rituximab and intravenous immunoglobulin
(IVIg). Fifteen patients received triple maintenance immu-
nosuppressive therapy consisting of tacrolimus, mycophe-
nolate mofetil, and a corticosteroid. Two patients had an
early graft loss, one owing to hypovolemic shock at the day 4
after KT, the other owing to vascular thrombosis at day 4
after KT. Two patients died, one owing to hypovolemic shock
at day 4 after KT, and other at 2 months after KT, with a
948 QUERIDO, MACHADO, SILVA ET ALfunctioning graft, owing to H1N1 infection. One patient has
been coinfected with polyomavirus BK 4 months after KT
and his immunosuppressive regimen was changed to siroli-
mus, tacrolimus, and prednisone.
All recipients under antiretroviral therapy were main-
tained on previous cART; the patient who had never been
under antiretroviral therapy before KT started cART after
the procedure. All 5 patients who were under ritonavir-
boosted protease inhibitors remained on this drug regimen.
However, it was necessary to reduce substantially the dose of
tacrolimus to achieve therapeutic range.
Humoral rejection was detected in 2 patients and cellular
rejection in 3. The 3 patients with acute cellular rejection
were treated with steroid pulses, with recovery of previous
renal function. The 2 patients with acute humoral rejection
were treated, 1 with plasmapheresis, rituximab, and IVIg,
and the other with thymoglobulin, plasmapheresis, and
IVIg. The ﬁrst developed an acute humoral rejection
episode after a signiﬁcant reduction in the immunosup-
pression, in the context of coinfection with polyomavirus
BK. Both cases of humoral rejection recovered the previous
eGFR. At the date of last follow-up, average time after KT
was 17  14 months. The last eGFR were 64.58  22.34 mL/
min/1.73 m2. We summarize the results in Table 1.DISCUSSION
Given the increased life expectancy since the introduction
of cART, HIV-positive patients develop long-term compli-
cations, such as ESRD. In the United States and Europe,
1%e1.5% of patients with ESRD are infected with HIV
[3,4] and most of them are on dialysis owing to HIVAN.
HIVAN is considered less common in Europe than in the
United States. In our series, 4 patients (23.5%) had HIVAN
diagnosed as the cause of their ESRD. We cannot exclude
that HIVAN could be the cause of the ESRD of the patients
whose etiology was undetermined.
The prevalence of HCV infection in HIV-infected pop-
ulations is high [11]. CoinfectionwithHCVwasbeendescribed
as a negative graft survival factor, possibly owing to longer
times on dialysis and duration of HIV infection. Although the
evolution of HCV may be more aggressive in HIV-positive
patients, KT in patients simultaneously positive for HCV and
HIV infection has shown better results than dialysis [12,13]. In
our case, the HCV coinfection rate was 11.8%, lower than the
prevalence shown in some published literature [12].
Induction and maintenance therapy in HIV positive pa-
tients varies in different series [12e16] and raises some
challenging questions. Several antiretrovirals are metabo-
lized through cytochrome P450 (CYP450) and they may
affect the function of this hepatic enzyme and P-glycopro-
tein (PGP) in the bowel. Ritonavir is used to boost protease
inhibitors and is a potent CYP450 and PGP inhibitor. Cal-
cineurin inhibitors and mammalian target of rapamycin in-
hibitors are metabolized in the liver through the CYP450
enzymatic system. Thus, the interactions between the 2
drugs lead to extremely high immunosuppressant levels. Theuse of integrase inhibitor-based regimens, such as ralte-
gravir, may be useful to avoid those interactions.
The majority of our patients (94.1%) received induction
therapy, 70.5% of them with basiliximab and 29.5% with thy-
moglobulin. In the United States, 83% of patients received
induction therapy, 51% of them with anti-CD25 [15]. In a
French series, 100% of patients received induction therapy
[16]. All patients of our series received triple maintenance
immunosuppressive therapy, which included tacrolimus. The 5
patients who were receiving ritonavir-boosted protease in-
hibitors, maintained this drug, however, with the need to
drastically reduce the dose of tacrolimus.
We report a rate of AR of 29.4%, slightly lower than that
reported in the literature [12,13,15,16]. The European andUS
studies describea 1-year graft survival between90.4%and98%
[12,15,16].Wehad 2 cases of early graft loss, with a 1-year graft
survival of 88.25%, equal to the patient survival. In our series,
follow-up was 17  14 months, which is insufﬁcient to accu-
rately estimate graft survival. Thesedata reﬂect thePortuguese
experience and are consistent with the literature results.
In conclusion, as in other series, KT seems to be an accept-
able alternative to dialysis in selected HIV-positive patients,
even in those with AIDS criteria in the past; however, high
rejection rates can be expected.When the disease is controlled,
and after the reconstitution of the immune system with cART,
KT should be considered according to the riskebeneﬁt ratio for
each patient.REFERENCES
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